Amneal Pharmaceuticals, Inc. (AMRX), Friday announced financial outlook for the fiscal year 2025.
The company sees revenue in the range of $3.0 billion to $3.1 billion for the full year 2025.
Analysts, on average, estimate revenue of $2.92 billion for the same period.
The company projects adjusted earnings of $0.65 to $0.70 per share for the year.
Analysts, on average, expect earnings of $0.71 per share for the same year.
In the pre-market hours, Amneal's stock is trading at $8.60, up 2.63 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.